News
Mizuho's Jared Holz joins 'Fast Money' to talk what is next for Novo Nordisk as the stock struggles.
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.
Explore more
The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...
The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...
7don MSN
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
Helping compensate for the funding shortfall is the Novo Nordisk Foundation, which has pledged up to 380 Danish kroner ($58 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results